Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3038% below fair value
$0.53−0.01 (-2.41%)
Close on Nov 13, 2026Market cap $81.19MP/E –Yield –
Coherus Oncology ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Coherus Oncology's ebitda for the twelve months ending Sep 30, 2026 was -$147.14M. For fiscal 2025 it was -$179.83M. The highest annual figure on record is $159.21M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$179.83M | – |
| FY2024 | Dec 31, 2024 | -$198.05M | – |
| FY2023 | Dec 31, 2023 | -$200.00M | – |
| FY2022 | Dec 31, 2022 | -$253.28M | – |
| FY2021 | Dec 31, 2021 | -$260.36M | -263.5% |
| FY2020 | Dec 31, 2020 | $159.21M | +43.4% |
| FY2019 | Dec 31, 2019 | $111.03M | – |
| FY2018 | Dec 31, 2018 | -$201.18M | – |
| FY2017 | Dec 31, 2017 | -$228.74M | – |
| FY2016 | Dec 31, 2016 | -$112.94M | – |
| FY2015 | Dec 31, 2015 | -$217.20M | – |
| FY2014 | Dec 31, 2014 | -$64.01M | – |
| FY2013 | Dec 31, 2013 | -$35.59M | – |
| FY2012 | Dec 31, 2012 | -$38.30M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$32.80M | – |
| Q2 FY2026 | Jun 30, 2026 | -$31.47M | – |
| Q1 FY2026 | Mar 31, 2026 | -$35.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$47.61M | – |
| Q3 FY2025 | Sep 30, 2025 | -$44.03M | – |
| Q2 FY2025 | Jun 30, 2025 | -$45.19M | – |
| Q1 FY2025 | Mar 31, 2025 | -$44.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$45.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$46.46M | – |
| Q2 FY2024 | Jun 30, 2024 | -$39.13M | – |
| Q1 FY2024 | Mar 31, 2024 | -$67.19M | – |
| Q4 FY2023 | Dec 31, 2023 | -$68.21M | – |
| Q3 FY2023 | Sep 30, 2023 | -$31.21M | – |
| Q2 FY2023 | Jun 30, 2023 | -$33.74M | – |
| Q1 FY2023 | Mar 31, 2023 | -$66.85M | – |
| Q4 FY2022 | Dec 31, 2022 | -$50.49M | – |
| Q3 FY2022 | Sep 30, 2022 | -$79.55M | – |
| Q2 FY2022 | Jun 30, 2022 | -$43.11M | – |
| Q1 FY2022 | Mar 31, 2022 | -$80.16M | – |
| Q4 FY2021 | Dec 31, 2021 | -$38.67M | -324.0% |
| Q3 FY2021 | Sep 30, 2021 | -$31.89M | -192.7% |
| Q2 FY2021 | Jun 30, 2021 | -$23.26M | -135.2% |
| Q1 FY2021 | Mar 31, 2021 | -$166.51M | -501.5% |
| Q4 FY2020 | Dec 31, 2020 | $17.27M | -62.5% |
| Q3 FY2020 | Sep 30, 2020 | $34.42M | -34.6% |
| Q2 FY2020 | Jun 30, 2020 | $66.01M | +134.1% |
| Q1 FY2020 | Mar 31, 2020 | $41.48M | – |
| Q4 FY2019 | Dec 31, 2019 | $46.09M | – |
| Q3 FY2019 | Sep 30, 2019 | $52.64M | – |
| Q2 FY2019 | Jun 30, 2019 | $28.19M | – |
| Q1 FY2019 | Mar 31, 2019 | -$15.91M | – |
| Q4 FY2018 | Dec 31, 2018 | -$59.89M | – |
| Q3 FY2018 | Sep 30, 2018 | -$56.17M | – |
| Q2 FY2018 | Jun 30, 2018 | -$44.01M | – |
| Q1 FY2018 | Mar 31, 2018 | -$41.11M | – |
| Q4 FY2017 | Dec 31, 2017 | -$45.54M | – |
| Q3 FY2017 | Sep 30, 2017 | -$55.82M | – |
| Q2 FY2017 | Jun 30, 2017 | -$55.80M | – |
| Q1 FY2017 | Mar 31, 2017 | -$71.55M | – |
| Q4 FY2016 | Dec 31, 2016 | -$72.66M | – |
See a number that looks wrong?